Currently, commercially marketed insulin infusion sets are cleared by FDA for up to three days of use. Through its collaboration with JDRF, BD is planning to address the mechanical, material, and ...

which is designed for improved insulin flow with reduced interruptions. Now the FDA has cleared the new infusion set based on BD FlowSmart. The infusion set is the result of a collaboration ...

Because their bodies fail to respond to insulin correctly, these patients need higher doses to manage their disease. The FDA green-lighted the BD U-500 Insulin Syringe in July, while Lilly picked ...

Through this agreement, Julphar’s human insulin formulations, including Jusline R, Jusline N and Jusline 30/70, will be available for administration through BD’s portfolio of BD Vystra ...